TVI Biliary 1
Alternative Names: TVI-Biliary-1Latest Information Update: 15 Jan 2024
At a glance
- Originator TVAX Biomedical
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Biliary cancer
Highest Development Phases
- Preclinical Biliary cancer
Most Recent Events
- 12 Oct 2023 TVI Biliary 1 is available for licensing as of 10 Oct 2023. http://www.tvaxbiomedical.com/clinical-data.shtml
- 10 Oct 2023 Preclinical trials in Biliary cancer (Prevention) in USA (Parenteral) (TVAX Biomedical pipeline, October 2023)
- 10 Oct 2023 Preclinical trials in Biliary cancer in USA (Parenteral) (TVAX Biomedical pipeline, October 2023)